Table 3. Rosuvastatin Camparator-Controlled Trials in Patients with Primary Hypercholesterolemia

Study	N	Treatments (dose/day)	Results
			% of LDL-Cholesterol Reduction from Baseline	% of Patients Achieving ATP-II or -III Targets
Olsson et al. 200114 Randomized, open-label, comparator- and placebo-controlled trial 6 weeks	142	Rosuvastatin 1-40 mg	34-65	N/A
		Atorvastatin 10 mg	44
		Atorvastatin 80 mg	59
		Placebo	-3.6
Paoletti et al. 200115 Randomized, double-blind, multi-center, comparatory-controlled trial 12 weeks	502	Rosuvastatin 5 mg	42	71
		Rosuvastatin 10 mg	49	87
		Pravastatin 20 mg	28	53
		Simvastatin 20 mg	37	64
Brown et al. 200216 Randomized, double-blind, multi-center, comparator-controlled trial	Fixed Dose Period 12 wks 477	Rosuvastatin 5 mg	39	80
		Rosuvastatin 10 mg	47	90
		Pravastatin 20 mg	27	53
		Simvastatin 20 mg	35	69
	Dose Titration Period 52 wks 477	Rosuvastatin 5-80 mg	42	88
		Rosuvastatin 10-80 mg	48	88
		Pravastatin 40 mg	32	60
		Simvastatin 80 mg	38	73
Olsson et al. 200217 Randomized, double-blind, multi-center, comparator-controlled trial	Fixed Dose Period 12 wks 412	Rosuvastatin 5 mg	46	86
		Rosuvastatin 10 mg	50	73
		Atorvastatin 10 mg	39	86
	Dose Titration Period 52 wks 412	Rosuvastatin 5-80 mg	47	88
		Rosuvastatin 10-80 mg	53	98
		Atorvastatin 80 mg	44	87
Davidson et al. 200218 Randomized, double-blind, multi-center, comparator- and placebo-controlled trial 12 weeks	516	Rosuvastatin 5 mg	40	84
		Rosuvastatin 10 mg	43	82
		Atorvastatin 10 mg	35	72
		Placebo	0	12

Adapted from Olsson AG et al. Am J Cardiol 2001; 88:504-8, Paoletti R et al. J Cardiovasc Risk 2001:8:383-90, Brown WV et al. Am Heart J 2002; 144: 1036-43, Olsson AG et al. Am Heart J 2002;144:1044-51, Davidson M et al. Am J Cardiol 2002;89:268-75.

Return to Article